766 A clinical trial to evaluate the safety, tolerability and preliminary efficacy of VG161 in combination with Nivolumab in patients with advanced pancreatic cancer

• Tian Fang,
• Wei Song,
• Tingbo Liang,
• Xueli Bai,
• Yuwei Li,
• Qian Tan,
• Yinan Shen,
• Xingmei Liang,
• Xinyan Jin,
• Ronghua Zhao,
• Aijun Qin,
• Yiting Qiu

Affiliations

Tian Fang

3The First Affiliated Hospital, ZJU, Hangzhou, Zhejiang, China

Wei Song

Department of Neurology, Laboratory of Neurodegenerative Disorders, Rare disease center, West China Hospital, Sichuan University, Chengdu, China

Tingbo Liang

Cancer Center, Zhejiang University, Hangzhou, China

Xueli Bai

4 The Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province, Hangzhou, China

Yuwei Li

School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, Guangdong, China

Qian Tan

Department of Orthopedic Surgery, Hunan Children`s Hospital, Changsha, Hunan, China

Yinan Shen

1The First Affiliated Hospital, ZJU, Hangzhou, China

Xingmei Liang

1The First Affiliated Hospital, ZJU, Hangzhou, China

Xinyan Jin

1The First Affiliated Hospital, ZJU, Hangzhou, China

Ronghua Zhao

3Virogin Biotech, Vancouver, Canada

Aijun Qin

2Virogin Biotech (Shanghai) Ltd, Shanghai, China

Yiting Qiu

2Virogin Biotech (Shanghai) Ltd, Shanghai, China